Search results
Showing 3451 to 3465 of 8222 results
Home {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/","name":"Home"}}]}
Our content assurance service. Includes what the service offers, how to apply and pricing.
Our public task statement, which sets out the mandatory functions which NICE is under a legal duty to perform.
Embed NICE content in your digital products and services with our syndication API.
Using our content internationally. Includes information on fees and licensing agreements for both AI and non AI requests.
Using NICE content for AI purposes. Includes complete content, adaptation, contextualisation, translation, selected extracts and the use of our COVID-19 content internationally.
Learn more about what NICE content is available for reuse by checking our information asset register.
Learn about situations where you cannot use NICE content.
Find out how and where you can reuse NICE's content. Includes use of our content in the UK, use of our content internationally, use of our content for AI purposes, our content assurance process, and our information asset register.
Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)
RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.
How we collect and use your personal information, and your rights under data protection legislation.
Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.
Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.
Agenda and papers of the NICE public board meeting on 10 December 2025
Agenda and papers of the NICE public board meeting on 19 January 2022